Status:
COMPLETED
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Lymphocytic Leukemia, Chronic
Eligibility:
All Genders
18+ years
Brief Summary
This multi-center, prospective, observational study will describe the management of relapsing or refractory chronic lymphocytic leukemia (CLL) patients. Data will be collected for 2 years.
Eligibility Criteria
Inclusion
- Adult patients, \>/=18 years of age
- Diagnosis of relapsed or refractory chronic lymphocytic leukemia (CLL) with first or second relapse
- Previous treatment with MabThera/Rituxan
- MabThera/Rituxan treatment planned for current relapse
Exclusion
- Richter syndrome
- Life expectancy \<6 months
Key Trial Info
Start Date :
April 4 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 24 2016
Estimated Enrollment :
327 Patients enrolled
Trial Details
Trial ID
NCT01488162
Start Date
April 4 2011
End Date
October 24 2016
Last Update
March 22 2017
Active Locations (84)
Enter a location and click search to find clinical trials sorted by distance.
1
Aix-en-Provence, France, 13616
2
Aix-en-Provence, France, 13617
3
Albi, France, 81030
4
Angers, France, 49933